Table 2 Monthly migraine days, monthly headache days, and monthly days with acute medication use across the observation period in patients treated with the CGRP-R mAb erenumab and patients treated with the CGRP-mAbs galcanezumab or fremanezumab

Monthly migraine days

Baseline

Last treatment month

3 months after discontinuation

3 months after restart

Erenumab

12.9 ± 3.6

9.1 ± 5.7

14.5 ± 6.9

8.7 ± 6.1

Galcanezumab/ Fremanezumab

11.8 ± 6.4

6.4 ± 4.7

10.8 ± 5.5

7.1 ± 5.1

Monthly headache days

Baseline

Last treatment month

3 months after discontinuation

3 months after restart

Erenumab

14.9 ± 5.1

9.6 ± 5.6

15.2 ± 6.4

9.0 ± 5.8

Galcanezumab/ Fremanezumab

13.0 ± 7.2

6.4 ± 4.6

11.1 ± 5.3

7.4 ± 5.1

Monthly days with acute medication

Baseline

Last treatment month

3 months after discontinuation

3 months after restart

Erenumab

11.6 ± 4.2

6.6 ± 4.6

10.3 ± 6.2

5.1 ± 4.0

Galcanezumab/ Fremanezumab

10.7 ± 6.1

5.4 ± 4.7

9.0 ± 4.6

6.2 ± 5.1